RxDoctor Payments Data

Tana Gonzalez

Gerontology · York, PANPI 1407866395

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,632in general payments, 2019–2025

Across 130 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$423
  • Sumitomo Pharma America, Inc.$396
  • 180 Medical, Inc.$278
  • Coloplast$267
  • Teleflex LLC$183
  • AbbVie$151
  • plus $934 from 19 others

What the payments were for

  • Food & beverage$2,56097%
  • Education$723%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,632 in reported general payments places this provider in the 90th percentile of 383 gerontology providers in Pennsylvania.

See all gerontology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$99,419
Medicare patients
803
Services billed
1,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron202$161,598
GemtesaVibegron69$41,497
Tamsulosin Hcl1,222$19,419
Finasteride759$10,617
Methenamine Hippurate144$10,482
Potassium Citrate ErPotassium Citrate110$10,158
Tolterodine Tartrate ErTolterodine Tartrate118$9,493
Trimethoprim128$6,810
Oxybutynin Chloride ErOxybutynin Chloride141$6,376
Trospium Chloride ErTrospium Chloride45$5,858
Estradiol55$5,713
Cefpodoxime Proxetil38$5,343
Testosterone29$3,804
Dutasteride166$3,764
NitrofurantoinNitrofurantoin Macrocrystal71$3,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$423$161,598202 claims
Sumitomo Pharma America, Inc.Gemtesa$396$41,49769 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 383 gerontology providers in Pennsylvania.

Other gerontology in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →